Overview
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Background
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indication
Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Associated Conditions
- Aluminum overload
- Chronic Iron Overload
- Chronic aluminum overload
- Iron Overload
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/17 | Phase 2 | Not yet recruiting | |||
2025/01/08 | Phase 3 | Recruiting | |||
2024/06/21 | Not Applicable | Completed | |||
2024/04/08 | Phase 3 | Recruiting | |||
2023/02/28 | N/A | Completed | Aswan University Hospital | ||
2022/03/29 | Phase 2 | Recruiting | Sun Yat-sen University | ||
2022/01/11 | Phase 1 | Recruiting | |||
2020/11/18 | Phase 2 | Completed | |||
2020/09/28 | Phase 2 | Recruiting | Aditya S. Pandey, MD | ||
2020/05/15 | Phase 4 | UNKNOWN | Hesham Al-Inany |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Apotex Corp. | 60505-6236 | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 500 mg in 1 1 | 12/1/2023 | |
| Hospira, Inc. | 0409-2336 | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 500 mg in 1 1 | 3/1/2023 | |
| ApoPharma USA, Inc. | 52609-4505 | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 500 mg in 1 1 | 10/7/2017 | |
| Hospira, Inc. | 0409-2337 | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 2 g in 1 1 | 3/1/2023 | |
| Alvogen Inc. | 47781-624 | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 2 g in 1 1 | 10/7/2017 | |
| Fresenius Kabi USA, LLC | 63323-597 | INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS | 95 mg in 1 mL | 5/16/2017 | |
| Apotex Corp. | 60505-6237 | INTRAMUSCULAR, INTRAVENOUS | 2 g in 1 1 | 12/1/2023 | |
| Novartis Pharmaceuticals Corporation | 0078-0467 | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 500 mg in 1 1 | 9/9/2022 | |
| Alvogen Inc. | 47781-623 | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 500 mg in 1 1 | 10/7/2017 | |
| Fresenius Kabi USA, LLC | 63323-599 | INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS | 95 mg in 1 mL | 5/16/2017 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 500 mg/vial | SIN09794P | INJECTION, POWDER, FOR SOLUTION | 500 mg/vial | 6/4/1998 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Desferrioxamine Mesilate for Injection | 国药准字HJ20170147 | 化学药品 | 注射剂 | 12/20/2021 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Hospira Desferrioxamine Mesilate 500 mg Powder for Injection vial | 137516 | Medicine | A | 4/16/2007 | |
| Hospira Deferoxamine Mesylate 500 mg Powder for Injection Vial | 378150 | Medicine | A | 11/17/2021 | |
| DBL DESFERRIOXAMINE MESYLATE FOR INJECTION 500mg powder for injection | 53942 | Medicine | A | 1/11/1996 | |
| Hospira Desferrioxamine mesilate for Injection BP, 500 mg | 162013 | Medicine | A | 5/27/2009 | |
| Desferoxamine Mesylate For Injection 2 g per vial | 315120 | Medicine | A | 3/6/2019 | |
| DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 2g/vial | 73173 | Medicine | A | 2/24/2000 | |
| Hospira Desferrioxamine Mesilate for Injection, BP 500 mg/vial | 144548 | Medicine | A | 9/11/2007 | |
| Hospira Desferrioxamine Mesilate for Injection 2g/vial | 67277 | Medicine | A | 12/16/1998 |